Dudediligence.

BridgeBio Pharma, Inc

BBIONASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$2.7MSep ’24$5.9MDec ’24$116.6MMar ’25$110.6MJun ’25$120.7MSep ’25$154.2MDec ’25$194.5MMar ’26$243.7MJun ’26
Net income, by quarter
−$164.3MSep ’24−$267.4MDec ’24−$169.6MMar ’25−$183.8MJun ’25−$184.9MSep ’25−$194.6MDec ’25−$166.6MMar ’26−$155.9MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$69.7M$77.6M$9.3M$221.9M$502.1M
Gross profit$66.6M$74.2M$6.9M$218.0M$481.1M
Operating income−$576.6M−$512.2M−$607.4M−$593.0M−$523.4M
Net income−$586.5M−$484.7M−$653.3M−$543.3M−$732.9M
Operating cash flow−$497.9M−$419.5M−$527.7M−$520.7M−$445.9M
Free cash flow−$511.2M−$424.3M−$529.0M−$521.7M−$447.0M
Cash$393.8M$376.7M$375.9M$681.1M$570.1M
Debt$430.8M$431.0M$446.4M$437.3M$2.01B
Shares outstanding147.3M150.6M175.1M190.0M194.8M